ImmuCell Corporation
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from ImmuCell Corporation's yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Tangible Net Worth Ratio: Of every $100 of net worth, $100 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than 95% of Healthcare companies in United States.
- Tangible Assets Ratio: Of every $100 the company owns, $100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 95% of Healthcare companies in United States.
- Cash Locked Ratio: For every $100 of sales, $43 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $38 tied up three years earlier. More money tied up than 85% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-0.5×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Higher than 62% of Healthcare companies in United States.
Cash Locked Ratio
$43For every $100 of sales, $43 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $38 tied up three years earlier.
More money tied up than 85% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
2/3 · 2/3Sales grew in 2 of the last 3 years; profit grew in 2 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
$16Sales grew 49% in 3 years; of every extra $100 of sales, $16 became extra profit.
Lower than 54% of Healthcare companies in United States.
Asset Productivity Ratio
+49% / -5%In 3 years sales changed by +49% while total assets changed by -5%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
1.5×Debt due within a year is covered 1.5 times by its yearly operating cash.
Higher than 73% of Healthcare companies in United States.
Cash Cushion Ratio
−10%Debt, after subtracting cash, equals 10% of its market value (net debt).
Lower than 78% of Healthcare companies in United States.
Tangible Assets Ratio
100%Of every $100 the company owns, $100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 95% of Healthcare companies in United States.
Tangible Net Worth Ratio
100%Of every $100 of net worth, $100 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 95% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
ImmuCell Corporation owes $0.33 for every $1 it owns. ImmuCell Corporation made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
149.1Investors pay $149.1 for every $1 of ImmuCell Corporation's yearly profit, higher than 94% of Healthcare companies in United States.
P/B ratio
3.02The share price is 3.02 times ImmuCell Corporation's book value per share, higher than 56% of Healthcare companies in United States.
Market cap
$95 MThe total market value of all of ImmuCell Corporation's shares at today's price (share price × number of shares), smaller than 66% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$31 MWhat ImmuCell Corporation would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$3.45Net worth divided by the number of shares. The share price of $10.44 is 3.0 times this, which is the P/B above.
Return on equity (ROE)
2.6%ImmuCell Corporation earned 2.6% on its shareholders' money over the last year, higher than 78% of Healthcare companies in United States.
Owes vs Owns
0.33×ImmuCell Corporation owes $0.33 for every $1 it owns (low), lower than 57% of Healthcare companies in United States.
Dividend yield
NoneImmuCell Corporation does not currently pay a dividend.
Revenue growth
+4%Revenue rose 4% in the year to Dec 2025, and grew 14% a year on average over 3 years.
Profit growth
LossImmuCell Corporation made a loss in each of the last two years.
Profit margin
-3.8%ImmuCell Corporation lost $4 for every $100 of revenue.
Interest cover
3.8×ImmuCell Corporation's operating profit covered its interest costs 3.8 times in the year to Dec 2025.
Cash vs debt
Net debtImmuCell Corporation had $9 M more debt than cash (net debt) at Dec 2025.
Questions
What is ImmuCell Corporation's P/E ratio?
Investors pay $149.1 for every $1 of ImmuCell Corporation's yearly profit, higher than 94% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For ImmuCell Corporation: $95 M ÷ $31 M (30 Jun 2026) = 3.0.
What is ImmuCell Corporation's return on equity?
ImmuCell Corporation earned 2.6% on its shareholders' money over the last year, higher than 78% of Healthcare companies in United States.
How much does ImmuCell Corporation owe compared with what it owns?
ImmuCell Corporation owes $0.33 for every $1 it owns (low), lower than 57% of Healthcare companies in United States.
Does ImmuCell Corporation pay a dividend?
No. ImmuCell Corporation does not currently pay a dividend.
Is ImmuCell Corporation's revenue growing?
Revenue rose 4% in the year to Dec 2025, and grew 14% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.